The post-acute sequelae of SARS-CoV-2 infection — “long COVID” in lay framing, PASC in clinical literature — generated a distinct Indian respiratory-clinic population: patients discharged from hospital on supplemental oxygen in 2021–22, many of whom continued to need oxygen at home for months and some for years. Five years on, what we have learned about this group is substantive — who weans, how fast, and what the diagnosis actually is when a “long-COVID oxygen patient” turns out to be harbouring something else. This article reviews the 2024–26 evidence position, the reassessment cadence, and the rent-versus-buy economics of a condition that often turns out to be finite in duration.
The audience is the pulmonologist reviewing a post-COVID oxygen patient at their first or second follow-up, the home-care dealer fielding rental enquiries from post-COVID families, and the patient or family trying to understand whether the oxygen requirement is permanent.
The post-COVID oxygen population
The Indian second wave (April–June 2021) produced an unprecedented oxygen-dependent discharge volume. Tertiary hospitals discharged patients on 2–6 L/min concentrators who, pre-pandemic, would have been ICU inpatients. The 2021 cohort is the base population for most of the Indian and international data on post-COVID LTOT trajectories.
The sub-populations within “post-COVID oxygen”:
Post-ARDS fibrosis. Patients who survived severe COVID pneumonitis with ground-glass and consolidation evolving to fibrotic changes. Variable degrees of fibrosis, variable reversibility.
Cryptogenic organising pneumonia (COP) post-COVID. A steroid-responsive pattern that often resolves with 3–6 months of prednisolone taper. This subgroup frequently weans off oxygen.
Pulmonary thromboembolism sequelae. COVID-associated thromboembolic disease with chronic thromboembolic pulmonary hypertension in a small subgroup. Persistent hypoxaemia here is a different mechanism and requires different workup.
Reactivation or new-onset reactive airways disease. A subset of post-COVID patients develops asthma-like or post-infectious bronchiectasis patterns that mimic LTOT-requiring fibrotic disease. These patients respond to inhaler therapy; oxygen often becomes unnecessary.
Undiagnosed pre-existing ILD unmasked by COVID. A patient with sub-clinical IPF or CTD-ILD may have been asymptomatic pre-COVID, developed severe COVID pneumonitis, and emerged with unmasked fibrotic disease. “Post-COVID oxygen” is a misnomer; the diagnosis is IPF or NSIP with a COVID insult on top.
The last category is the critical clinical trap. A patient who is “still on oxygen 14 months after COVID” should have HRCT, PFT with DLCO, and autoimmune workup to distinguish post-COVID fibrosis from pre-existing ILD that the COVID episode merely brought to light.
Weaning rates — what the data says
Indian cohort reports, 2022–25, converge on broadly consistent weaning statistics:
- At 3 months post-hospital discharge, ~40–55% of patients have weaned off supplemental oxygen.
- At 6 months, ~55–70% have weaned.
- At 12 months, ~60–75% have weaned.
- At 24 months, ~70–85% have weaned.
- A residual 15–25% remain oxygen-dependent beyond 24 months; many of these are the “unmasked pre-existing ILD” or severe-fibrosis subgroups.
International data from European and American cohorts shows similar directions with some cohort-specific variation. The Italian and UK cohorts, for instance, have reported 12-month weaning rates in the 55–70% range.
The practical clinical implication: most post-COVID oxygen patients will wean off, and the probability of weaning is high enough that the prescription should be structured as a time-limited trial with a defined reassessment schedule, not as a permanent LTOT installation.
Reassessment cadence
A defensible post-COVID LTOT reassessment schedule:
At 6 weeks post-discharge. First clinic visit. Clinical assessment, resting SpO₂, short walk to assess exertional desaturation. If resting SpO₂ consistently ≥ 92% and exertional SpO₂ ≥ 88%, trial off oxygen for 24 hours supervised. Many patients come off at this visit.
At 3 months. PFT with DLCO, HRCT if not already done, 6-minute walk test. This is the decision point for patients who remain oxygen-dependent — decide whether the trajectory is post-infectious recovery (continue with reassessment) or whether an alternative diagnosis (IPF, NSIP, COP, CTEPH) needs to be pursued.
At 6 months. Repeat PFT, 6MWT. A second decision point. Patients still on oxygen at 6 months with persistent fibrotic HRCT changes and reduced DLCO should have a multidisciplinary ILD review — this is the population where “post-COVID” becomes “post-COVID fibrotic ILD” and the management shifts toward antifibrotic therapy consideration.
At 12 months. PFT, 6MWT, consider autoimmune workup if not already done. Patients still on oxygen at 12 months are a smaller group with higher chance of chronic dependence. Begin conversation on long-horizon equipment needs.
Every 6 months thereafter until stable weaning or stable chronic dependence.
What PFT and HRCT actually add
PFT. Restrictive pattern with reduced DLCO is the post-COVID fibrosis signature. FVC and DLCO trends over 3–6 months distinguish recovery (improving) from progression (declining or stable at severely abnormal levels).
HRCT. Ground-glass opacities predominating with minimal reticulation suggest organising pneumonia, which is steroid-responsive. Honeycombing, traction bronchiectasis, and peripheral reticulation suggest fibrotic ILD — either post-COVID-induced or pre-existing IPF/NSIP unmasked. The radiological distinction matters for therapy selection.
Echo. A proportion of post-COVID oxygen patients have pulmonary hypertension that is the primary driver of oxygen need. Echo estimated pulmonary artery systolic pressure > 45 mmHg warrants further cardiology/ILD workup.
Autoimmune workup. ANA, ENA panel, RF, anti-CCP, myositis panel. A post-COVID oxygen patient with a newly-positive ANA pattern and interstitial changes may have CTD-ILD that the COVID episode precipitated or revealed.
When the diagnosis is actually something else
The common misdiagnoses within “post-COVID oxygen”:
Reactive airways disease. A patient with wheeze, variable symptoms, and response to bronchodilators was never primarily hypoxaemic — the oxygen dependence was a transient peri-infectious phenomenon. Formal PFT with reversibility testing sorts this out. Oxygen should be weaned; inhalers should be optimised.
Pulmonary fibrosis unmasked. A patient on oxygen 12+ months post-COVID, with fibrotic HRCT pattern, reduced DLCO, and no autoimmune markers, is very likely IPF. The COVID episode was an acute decompensation of sub-clinical disease. Treatment shifts to antifibrotic therapy (pirfenidone, nintedanib) and the oxygen prescription becomes long-term, following ILD rather than post-COVID rules.
Chronic thromboembolic pulmonary hypertension (CTEPH). A patient with persistent hypoxaemia and disproportionate exertional breathlessness, normal or improved CT parenchyma, but right ventricular dilatation on echo and elevated PASP, should have VQ scan and CT pulmonary angiogram. CTEPH is surgically treatable (pulmonary endarterectomy) in the right hands and is misdiagnosed as post-COVID LTOT in India with some regularity.
Deconditioning without hypoxaemia. A post-COVID patient who is breathless but has normal resting and exertional SpO₂ does not have a hypoxaemia problem. The prescription is pulmonary rehabilitation, not oxygen. Many Indian families expect and receive oxygen in this setting because the breathlessness is real and the family wants to do something; the honest prescription is rehab.
Equipment choices for post-COVID LTOT
For the post-COVID oxygen patient, equipment needs are typically modest and time-limited.
5 LPM stationary concentrator. The default. Flows of 2–4 L/min are typical at home; the 5 LPM reserve matters for exertional titration. A Nidek, Philips, Invacare, Oxymed, BPL, or Home Medix 5 LPM unit all serve this population adequately. Noise (45–48 dB), power draw (~350 W), and filter-change cadence are the operational variables — all are similar across mainstream brands.
10 LPM concentrator. Usually not needed. If a post-COVID patient is needing 6+ L/min resting, the diagnosis deserves re-examination (likely unmasked ILD, likely PH, likely inadequate CO₂ retention screening). Before scaling equipment up, rework the diagnosis.
Portable oxygen. For ambulatory use during recovery — work return, family outings, travel — a portable is reasonable. Continuous-flow portables (Philips SimplyGo, SeQual Eclipse 5, Respironics EverGo) deliver 2–3 LPM continuous with 4–5 hour battery at typical settings. Pulse-dose portables work for patients with normal respiratory rates and nasal breathing; they fail for tachypnoeic mouth-breathers, which is often the post-COVID population during early recovery.
Oximeter. A mid-tier consumer oximeter for home trending (BPL, Dr Trust, Control D, Beurer) at ₹1,500–3,500 is usually adequate. For the first 3 months, encourage the family to log morning, evening, and exercise-triggered readings to build a trajectory picture.
Rent-versus-buy economics
This is where post-COVID LTOT differs sharply from COPD LTOT.
A COPD LTOT patient expects to use the concentrator indefinitely. Purchase makes economic sense — amortised over 4–6 years of use, a ₹55,000 concentrator costs ~₹1,000/month plus electricity plus service.
A post-COVID LTOT patient expects to wean off in 3–24 months. The economic case flips.
Purchase (5 LPM concentrator, ₹45,000–70,000). Sunk cost. If the patient weans off at 6 months, ~₹7,500–12,000/month of effective cost, plus the device now sits idle or needs resale (second-hand market exists but at 40–60% of purchase price).
Rental (₹4,000–8,000/month in Indian metros for a 5 LPM concentrator with service). Pay only for months of actual use. At 6 months of use, total cost ₹24,000–48,000. At 12 months, ₹48,000–96,000. Only becomes less attractive than purchase beyond 12–18 months of expected use.
The honest prescription for a new post-COVID oxygen patient in 2026 is: rent, plan for weaning, reassess at 3 months. Purchase becomes defensible only after the patient has been stably oxygen-dependent for 12+ months and the PFT/HRCT workup has confirmed a chronic picture.
Indian home-care rental providers vary widely in service quality. Metro-tier providers offer contracts that include device swaps on fault, periodic filter changes, and emergency delivery. Tier-2/3 providers may offer a bare rental without service — ask specifically about what is included before signing.
Long COVID that never weans
The 15–25% of post-COVID oxygen patients who remain dependent at 24 months warrant specific comment.
This group overlaps heavily with the “unmasked pre-existing ILD” category. In practice, by month 24, the diagnostic label often shifts — the patient is no longer “post-COVID LTOT”, they are “post-COVID-induced fibrotic ILD” or “post-COVID CTEPH” or “post-viral bronchiectasis with chronic hypoxaemia”. The prescription continues as LTOT, but following the disease-specific management protocol rather than a generic post-COVID watching-for-weaning schedule.
For this subgroup, equipment needs may escalate toward the ILD profile — a 10 LPM concentrator, continuous-flow portable, closer dealer service — and purchase begins to make economic sense again.
Pulmonary rehabilitation — the under-used adjunct
A substantial fraction of post-COVID oxygen patients improve their functional status and oxygen requirement with structured pulmonary rehabilitation. The mechanism is not oxygen-mediated; it is deconditioning reversal, improved ventilatory efficiency, and psychological decoupling of breathlessness from distress. Indian tertiary centres with established pulmonary-rehab programmes (AIIMS, CMC Vellore, Hinduja, Sir Ganga Ram, KEM, some private chains) have reported meaningful functional improvement in post-COVID cohorts with 6–8 week programmes.
The practical barrier: pulmonary rehab is geographically concentrated. A post-COVID patient in a tier-3 city with no rehab programme relies on home-based exercise guidance, which is variable in quality. Video-based home rehab programmes emerged in 2021–22 and have persisted; the quality varies. For any post-COVID oxygen patient at 3–6 months from discharge who is still oxygen-dependent, ask whether a formal or structured home rehab programme is available — the functional benefit often exceeds any equipment upgrade.
Psychological dimension
Post-COVID respiratory distress has a substantial anxiety component in many patients. Breathlessness on exertion triggers panic, oxygen desaturation reading triggers panic, and the anxiety itself amplifies the breathlessness. This does not mean the oxygen need is “in the patient’s head” — the desaturation is real — but the functional impairment at a given saturation is modulated by the psychological overlay.
A patient who reads SpO₂ 92% and becomes acutely distressed has two problems: the saturation that is acceptable per LTOT criteria, and the distress that is not. Cognitive-behavioural strategies, breathing retraining, and in selected patients pharmacological anxiolysis are part of the management. A purely oxygen-focused approach misses this.
Regional variation in weaning rates
Published Indian post-COVID cohorts have reported weaning-rate variation across centres — some report 60% at 12 months, others 80%. Part of the variation reflects the severity-of-illness case mix during 2021–22 (a centre admitting primarily severe ARDS survivors will have slower weaning than one admitting a broader case mix), and part reflects post-discharge follow-up intensity. Patients in structured post-discharge programmes wean faster than patients lost to follow-up. The implication for prescribers: schedule follow-up and make the appointment easy to attend; post-COVID oxygen patients left to self-manage often remain on oxygen longer than clinically necessary.
Clinical takeaway
Post-COVID LTOT is usually time-limited. The 12-month weaning rate in Indian cohorts is 60–75%, so structure the prescription as a trial with reassessment at 6 weeks, 3 months, 6 months, and 12 months. PFT with DLCO and HRCT at 3 and 6 months sort recovery from progression; patients still oxygen-dependent at 12 months deserve a multidisciplinary ILD workup to distinguish post-COVID fibrosis from unmasked IPF, CTD-ILD, or CTEPH. Rental, not purchase, is the economically correct default for the first 12 months. A post-COVID patient needing 6+ L/min resting should have the diagnosis re-examined.
Consult your pulmonologist before changing post-COVID oxygen therapy; premature weaning in a patient with unrecognised fibrotic disease and prolonged oxygen in a patient who is ready to wean are both avoidable errors.